Do you or someone you know have experience with spasticity and Botulinum Toxin Type A injections?
SAFE invites you to participate in an international survey, conducted by Carenity, an online patient community, and biopharma Ipsen to help advance medical research and improve the lives of other patients.
Both patients and caregivers of patients with spasticity due to stroke (as well as traumatic brain injury or spinal cord injury) who are currently receiving Botulinum Toxin Type A injections or who have stopped receiving these injections less than a year ago can participate.
Botulinum toxin effect usually peaks around 4 to 6 weeks after injection, then it slowly decreases. This decrease is called the waning of botulinum toxin effect. The aim of this survey is to better understand patients’ experience with botulinum toxin type A injections, in particular:
– to better understand how patients experience the waning of botulinum toxin type A effects
– to identify the impact of the waning of botulinum toxin type A effects on the patient’s quality of life
– to describe patient populations profile
– to assess the reasons for stopping botulinum toxin type A injections
This survey will be the subject of communications during scientific congresses or scientific publications that will be redacted in collaboration with an international team of medical experts.
A synthesis of the results will be made available after the publications.
This international survey is conducted in Europe (France, Germany, Italy and the UK) and in the US until September 13th.
It is available in 4 languages:
English: https://member.carenity.co.uk/newSurveyBymail/0/38/0/0
French: https://membre.carenity.com/newSurveyBymail/0/107/0/0
German: https://member.carenity.de/newSurveyBymail/0/26/0/0
Italian: https://member.carenity.it/newSurveyBymail/0/25/0/0
Thank you very much for your participation!
Participation in this survey is unpaid.
To find out more about how your data will be processed and how to exercise your rights, read the survey information page, accessible when you click on the link provided above in this text.
